Navigation Links
As Billions in Blockbuster Drug Revenue Goes Off Patent, Life Sciences Companies are Challenged to Fundamentally Change Future R&D Strategies, According to New Deloitte Report
Date:4/2/2008

NEW YORK, April 2, 2008 /PRNewswire-USNewswire/ -- Pharmaceutical companies currently challenged with replacing the $65 billion worth of product expected to go off patent in the next four years must dramatically rethink their R&D models for future success, according to a new report released by Deloitte today.

According to the report titled The Changing Face of R&D in the Future Pharmaceutical Landscape (http://www.deloitte.com/us/FuturePharma), current R&D programs focused on developing a small portfolio of high revenue blockbusters will evolve to R&D programs focused on high efficacy treatments developed for smaller patient populations based on specific genotypes. Such treatments, and their higher demonstrated efficacy, may ultimately have the potential for higher per treatment revenues.

This fundamental disruption of today's pharmaceutical industry will create both opportunities and threats for current industry players, and will stimulate the emergence of new industry entrants configured specifically to succeed in the changed pharmaceutical landscape.

"Continuing yesterday's R&D focus on developing blockbusters will not secure success in the future," according to Terri Cooper, Ph.D., a principal in the Life Sciences practice of Deloitte Consulting LLP. "Pharmaceutical companies cannot rest on their laurels. They need to be looking outside of their four walls to develop partnerships and collaborations with a network of companies, scientists and organizations to fuel R&D developments and reduce time to bring new drugs to market."

The R&D model of the future will incorporate:

-- R&D strategies which support the assembly of treatment portfolios for the entire disease life cycle and the various genotype specific patient segments in the life cycle, rather than the traditional one-off "blockbuster"

-- Focused R&D programs based on genotyped patie
'/>"/>

SOURCE Deloitte
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Biogenerics Will Save Billions, Says Hospira CEO
2. So Long, Old Friend: The End of the Blockbuster Drug Era? What 2008 Holds for Bringing Drugs to Market
3. Merck Will Obtain Blockbuster Antidiabetic Drug Sales in Type 2 Diabetes Market by 2011
4. Novel Angiogenic Drugs, Including a Future Blockbuster from Genzyme, Could Revolutionize Treatment of Peripheral Arterial Disease
5. Plethora and Paul Capital Healthcare sign a $25 million revenue interest financing agreement with an option for an additional $3 million equity investment
6. Kiwa Bio-Tech Year-End Revenues Increase 264% - Exceed $9.1 Million
7. Neogen Reports 34% Increase in Net Income, 20% Increase in Revenues
8. Profarmas Gross Revenue Reached R$ 740,4 Million in the 4th Quarter of 2007, a 40,1% Growth Over the Same Period in the Last Year
9. Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36%
10. Phlo Reports Sharp Revenue Increase
11. Osteotech Reports 2007 Full Year and Fourth Quarter Financial Results; Full Year Revenue of $104.3 Million Exceeds $100 Million Milestone; Diluted Earnings Per Share Was $.15 in 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... Grace Century portfolio project, Provia Laboratories , ... the Board, to the National Stem Cell Ethics Committee ... by the Ministry of Health on behalf of the Government ... More than a year after Bahamian Parliament passed the ... Christie said the government has completed the accompanying regulations and ...
(Date:10/30/2014)... the key challenges in the development of quantum technologies ... In a paper published today (28 October) in ... how to make a new type of flexibly designed ... as high-precision sensors and specialised superfast computers, often depend ... methods for trapping these tiny particles are hugely problematic ...
(Date:10/27/2014)... 2014 The Italian company ... and sell its artificial "lower limb", after the ...      (Photo: http://photos.prnewswire.com/prnh/20141027/713097 ) ... the definitive judgement has arrived: Roadrunnerfoot, the small ... accessible hi-tech prostheses with composite materials, has won ...
(Date:10/27/2014)... October 27, 2014 New Q4-2014 ... SoundConnect , an industry leading unified communication and ... and agents to deliver cloud-based audio and web/video ... opportunities. , With SoundConnect’s Q4 incentive partners ... video and/or web conferencing licenses sold, now through ...
Breaking Biology Technology:Grace Century’s Stem Cell Biobank Project Announces Chairman’s Appointment to National Stem Cell Ethics Committee of The Bahamas 2Grace Century’s Stem Cell Biobank Project Announces Chairman’s Appointment to National Stem Cell Ethics Committee of The Bahamas 3Italian Lower Limb Prosthesis Company Wins Lawsuit Against German Giant Ottobock 2SoundConnect Unveils Q4 Partner Incentives 2
... computational tools and a state-of-the-art scanning transmission electron ... Iowa State University materials science and engineering researchers ... solid metallic materials known as metallic glasses. ... Review Letters , the findings fill a gap ...
... Richard Dolinar, chairman of the Alliance for Safe Biologic ... U.S. Food and Drug Administration (FDA) should resolve before ... in prepared testimony for the FDA,s May 11th public ... for the development of biosimilar products. ...
... May 10, 2012 Aviir Diagnostic Laboratory has entered ... as a participating provider with Stratose Network and their ... Stratose A true pioneer of claims ... PlanCare America, 4MOST Health, Qualident and KeyClaims) works to ...
Cached Biology Technology:In metallic glasses, researchers find a few new atomic structures 2In metallic glasses, researchers find a few new atomic structures 3Alliance for Safe Biologic Medicines Chairman Urges FDA to Ensure that Patient Safety is the Cornerstone of Biosimilar Pathway 2Aviir Laboratories Announce National Agreement with Stratose 2Aviir Laboratories Announce National Agreement with Stratose 3
(Date:10/29/2014)... 29, 2014, Beaverton, OR) New research presented ... International Conference in Houston, TX showed for the ... HPV infection in women using a readily available ... study, presented by Dr. Judith A. Smith, Pharm.D., ... and Reproductive Sciences at The University of Texas ...
(Date:10/29/2014)... is all the rage. Thousands of scientists worldwide are ... whether titanium dioxide nanoparticles from sun creams can get ... nanotubes from electronic products are as hazardous for the ... in food can get into the blood via the ... funds are flowing – and the number of scientific ...
(Date:10/29/2014)... the Barcode of Life Data Systems (BOLD). ... Data Journal (BDJ) used specimen records downloaded ... a human-readable text developed in manuscript within the ... study the species distributions of ten Nearctic species of ... originally designed to support the generation and application of ...
Breaking Biology News(10 mins):HPV infections in women eradicated by AHCC, Japanese mushroom extract 2Nanosafety research: The quest for the gold standard 2Nanosafety research: The quest for the gold standard 3Go straight and publish: From Barcode of Life Data Systems to scholarly publishing systems 2
... throwing unwanted fish overboard from commercial boats could put one ... say researchers at the University of Leeds. , New research ... which gannets rely on unwanted fish and offal thrown from ... "The North Sea has undergone massive environmental changes over the ...
... Scientists at the Lombardi Comprehensive Cancer Center at Georgetown University ... to tease apart in the most comprehensive way ever ... cells in cancer development and treatment. This protein determines which ... and how she will fare during her treatment. The researchers, ...
... NEW YORK, March 22, 2010 The Juvenile ... for diabetes research worldwide, said today that it will ... Organization, and The Hebrew University of Jerusalem on drugs ... type 1 diabetes. The program, under the ...
Cached Biology News:Fishing discard ban could damage sea bird success, scientists warn 2Lombardi receives $7.5 million grant for Breast Cancer Center for Cancer Systems Biology 2Lombardi receives $7.5 million grant for Breast Cancer Center for Cancer Systems Biology 3JDRF, Pfizer, Hadassah Medical and the Hebrew University announce collaboration 2
... traps a wide variety of solvent vapors that can ... flask (GCF400) allows for the collection of liquid into ... time minimizes waiting period., Ultra low -104 ... , Digital Display of ...
... RCT series of refrigerated cold traps offers ... of low volatility/aqueous solvents or high volatility ... other vacuum concentrators/centrifugal evaporators. Also used for ... such as used in electron microscopes. Can ...
... Trap is specifically designed for efficient ... as DMSO and DMF in the ... refrigeration system set at -5 o ... DMSO, while completely eliminating the risk ...
96 Well Plate Sterile, RE bottom; consistent medium binding affinity for hydrophobic complexes and proteins....
Biology Products: